The rise of healthcare AI makes trust a marketing issue
Healthcare has always bought cautiously. AI has sharpened that caution, and the public framework around it is becoming more defined: the MHRA has published guidance clarifying when ambient voice products are medical devices, NHS England has issued guidance for organisations adopting AI-enabled ambient scribing, and the National Commission into the Regulation of AI in Healthcare published recommendations for a future framework in September 2026.
In that environment, trust is not a soft attribute of your brand. It is the thing being assessed.
Overstatement is now a measurable cost
A claim that cannot survive a technical conversation does not just fail, it damages everything said around it. Buyers who catch one exaggeration re-read the rest of your material with suspicion, and they tell colleagues.
Transparency as positioning
Being clear about what your model does, what data it uses, where the human stays in the loop and what you have and have not evaluated is not a defensive disclosure exercise. Done well, it is the most persuasive content on your website, because almost nobody else is willing to be that specific.
Consistency between channels
Trust erodes quickly when the website, the sales deck, the LinkedIn posts and the tender response describe the product differently. In a long buying process with many stakeholders, inconsistency is visible in a way it never is in shorter B2B cycles.
Our position
We help companies communicate responsibly and credibly. We do not advise on clinical safety, regulatory classification or compliance. Those sit with specialists, and our work runs alongside theirs.
This article refers to a position current at the date above and is reviewed when the underlying guidance or policy changes. Clarity Media Co. comments on the marketing and commercial implications of developments in Digital Health and HealthTech. We do not provide clinical, regulatory, DTAC or legal advice.